The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C ...
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...
Sotorasib (Lumakras / Lumykras) is a acrylamide derivative, acts as antineoplastic agent. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of ...
The data breach exposes sensitive personal and medical information belonging to over 910,000 patients through ConnectOnCall, a telehealth platform and after-hours call service owned by Phreesia.
The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510 ... diagnostics from Guardant Health and Qiagen to identify patients eligible for treatment with the new drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback